Stockscreener 앱 받기
0.1851
11.73%
-0.0246
시간 외 거래:
.19
0.0049
+2.65%
전일 마감가:
$0.2097
열려 있는:
$0.21
하루 거래량:
258.78K
Relative Volume:
0.22
시가총액:
$11.94M
수익:
$1.16M
순이익/손실:
$-39.74M
주가수익비율:
-0.2985
EPS:
-0.62
순현금흐름:
$-35.02M
1주 성능:
-24.23%
1개월 성능:
-28.45%
6개월 성능:
+15.54%
1년 성능:
-93.31%
1일 변동 폭
$0.1826
$0.21
1주일 범위
$0.1826
$0.2473
52주 변동 폭
$0.1406
$2.86
Glycomimetics Inc Stock (GLYC) Company Profile
명칭
Glycomimetics Inc
전화
240-243-1201
주소
9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD
GLYC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GLYC
Glycomimetics Inc
|
0.1851 | 11.94M | 1.16M | -39.74M | -35.02M | -0.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 66.76B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Glycomimetics Inc Stock (GLYC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-07-26 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2023-12-22 | 개시 | CapitalOne | Overweight |
| 2021-11-12 | 업그레이드 | Jefferies | Hold → Buy |
| 2019-11-14 | 개시 | ROTH Capital | Buy |
| 2019-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-08-05 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2019-08-05 | 다운그레이드 | SunTrust | Buy → Hold |
| 2019-04-12 | 개시 | Piper Jaffray | Overweight |
| 2018-12-18 | 개시 | H.C. Wainwright | Buy |
| 2016-07-26 | 개시 | SunTrust | Buy |
| 2015-03-17 | 재확인 | Stifel | Buy |
모두보기
Glycomimetics Inc 주식(GLYC)의 최신 뉴스
Form 425 GLYCOMIMETICS INC Filed by: GLYCOMIMETICS INC - StreetInsider
GlycoMimetics (NASDAQ:GLYC) Now Covered by StockNews.com - Defense World
GLYCOMIMETICS Earnings Preview: Recent $GLYC Insider Trading, Hedge Fund Activity, and More - Nasdaq
Cantor Fitzgerald Begins Coverage on GlycoMimetics (NASDAQ:GLYC) - Defense World
Cantor Fitzgerald maintains Overweight on GlycoMimetics stock By Investing.com - Investing.com Australia
Cantor Fitzgerald Initiates Coverage of GlycoMimetics (GLYC) with Overweight Recommendation - MSN
GlycoMimetics (NASDAQ:GLYC) Coverage Initiated by Analysts at StockNews.com - Defense World
Cantor Fitzgerald maintains Overweight on GlycoMimetics stock - Investing.com India
Cantor Fitzgerald Initiates GlycoMimetics at Overweight -March 21, 2025 at 07:18 am EDT - Marketscreener.com
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
GlycoMimetics, Inc. (NASDAQ:GLYC) Short Interest Update - Defense World
StockNews.com Initiates Coverage on GlycoMimetics (NASDAQ:GLYC) - Defense World
GlycoMimetics, Inc. to Host Earnings Call - ACCESS Newswire
StockNews.com Begins Coverage on GlycoMimetics (NASDAQ:GLYC) - Defense World
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders - The Malaysian Reserve
GlycoMimetics, Inc. Announces Board Resignations -February 25, 2025 at 05:00 pm EST - Marketscreener.com
GlycoMimetics Says Following Termination, Co Will Not Have Any Material Financial Or Other Obligations Under Agreement - TradingView
GlycoMimetics ends key agreement; board members, executives depart By Investing.com - Investing.com South Africa
GlycoMimetics ends key agreement; board members, executives depart - Investing.com
GlycoMimetics Faces Leadership Changes Amid Board Resignations - TipRanks
US Penny Stocks To Watch In February 2025 - Yahoo Finance
Why GCL Global Holdings Shares Are Trading Higher By Around 107%; Here Are 20 Stocks Moving Premarket - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
GlycoMimetics (NASDAQ:GLYC) Coverage Initiated at StockNews.com - Defense World
Top 5 Biotech Stocks That Got Most Retail Buzz Last Week - NewsBreak
GlycoMimetics adjusts merger terms with Crescent Biopharma - MSN
GlycoMimetics And GENFIT Announce Significant Agreement Amendments - Evrim Ağacı
GlycoMimetics adjusts merger terms with Crescent Biopharma By Investing.com - Investing.com UK
GLYCOMIMETICS INC SEC 10-K Report - TradingView
GlycoMimetics (NASDAQ:GLYC) Now Covered by Analysts at StockNews.com - Defense World
Glycomimetics, Inc. Announces Cessation of Brian Hahn as Chief Financial Officer, No Later Than March 31, 2025 - Marketscreener.com
Glycomimetics, Inc. Announces Cessation of Harout Semerjian as Chief Executive Officer, No Later Than March 31, 2025 - Marketscreener.com
Reviewing PureTech Health (NASDAQ:PRTC) and GlycoMimetics (NASDAQ:GLYC) - Defense World
GlycoMimetics executives to depart amid merger plans By Investing.com - Investing.com South Africa
GlycoMimetics executives to depart amid merger plans - MSN
Should You Buy GlycoMimetics (GLYC) Ahead of Earnings? - MSN
GlycoMimetics and Crescent Biopharma Update Investor Presentation in Connection with Proposed Merger - Defense World
GlycoMimetics and Crescent Biopharma Announce Merger Plans - Yahoo Finance
Avacta Appoints Brian Hahn as Chief Financial Officer - The Manila Times
Avacta Appoints Brian Hahn as Chief Financial Officer - GlobeNewswire Inc.
Glycomimetics Inc (GLYC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.23%
1.63%
자본화:
|
볼륨(24시간):